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A B S T R A C T
Although cystic fibrosis (CF) patients exhibit signs of endothelial perturbation, the functions of the cystic fibrosis
conductance regulator (CFTR) in vascular endothelial cells (EC) are poorly defined. We sought to uncover
biological activities of endothelial CFTR, relevant for vascular homeostasis and inflammation. We examined cells
from human umbilical cords (HUVEC) and pulmonary artery isolated from non-cystic fibrosis (PAEC) and CF
human lungs (CF-PAEC), under static conditions or physiological shear. CFTR activity, clearly detected in
HUVEC and PAEC, was markedly reduced in CF-PAEC. CFTR blockade increased endothelial permeability to
macromolecules and reduced trans‑endothelial electrical resistance (TEER). Consistent with this, CF-PAEC dis-
played lower TEER compared to PAEC. Under shear, CFTR blockade reduced VE-cadherin and p120 catenin
membrane expression and triggered the formation of paxillin- and vinculin-enriched membrane blebs that
evolved in shrinking of the cell body and disruption of cell-cell contacts. These changes were accompanied by
enhanced release of microvesicles, which displayed reduced capability to stimulate proliferation in recipient EC.
CFTR blockade also suppressed insulin-induced NO generation by EC, likely by inhibiting eNOS and AKT
phosphorylation, whereas it enhanced IL-8 release. Remarkably, phosphodiesterase inhibitors in combination
with a β2 adrenergic receptor agonist corrected functional and morphological changes triggered by CFTR dys-
function in EC. Our results uncover regulatory functions of CFTR in EC, suggesting a physiological role of CFTR
in the maintenance EC homeostasis and its involvement in pathogenetic aspects of CF. Moreover, our findings
open avenues for novel pharmacology to control endothelial dysfunction and its consequences in CF.
1. Introduction
Cystic fibrosis (CF) is a genetic disease, caused by mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene [1].
The CFTR protein regulates Cl− and HCO3− secretion in ciliated and
serous cells of submucosal glands and ducts, and in epithelial cells
[2,3]. In the airways, CFTR dysfunction reduces the periciliary fluid
volume and impairs the mucociliary clearance, promoting infection,
inflammation and respiratory insufficiency [4]. CFTR dysfunction in
cells deputed to the immune-surveillance and host response can con-
tribute to CF pathogenesis [5–7].
The vascular endothelium is pivotal for the regulation of vascular
http://dx.doi.org/10.1016/j.bbadis.2017.08.011
Received 4 March 2017; Received in revised form 24 June 2017; Accepted 13 August 2017
⁎ Corresponding author at: Department of Medical, Oral and Biotechnological Sciences, CeSI-MeT, G. D'Annunzio University, Chieti-Pescara, Italy.
E-mail address: mromano@unich.it (M. Romano).
Abbreviations: AJ, adherent junctions; CFTR, cystic fibrosis conductance regulator; ECGF, endothelial cell growth factor; EMV, endothelial microvesicles; eNOS, endothelial nitric oxide
synthase; HUVEC, human umbilical vein endothelial cells; PAEC, pulmonary artery endothelial cells; PDE, phosphodiesterase; PKA, protein kinase A; TEER, trans‑endothelial electrical
resistance; TNF-α, tumor necrosis factor-α; YFP, yellow fluorescent protein
BBA - Molecular Basis of Disease 1863 (2017) 3243–3253
Available online 25 August 2017
0925-4439/ © 2017 Elsevier B.V. All rights reserved.
MARK
homeostasis and of the inflammatory response. It forms a semi-
permeable barrier between tissues and the bloodstream, thereby reg-
ulating solute transport and immune cells trafficking. The endothelial
barrier function is tightly controlled by intercellular adherence junc-
tions (AJ) and tight junctions, interconnected with cytoskeletal proteins
[8]. The transmembrane protein Vascular Endothelial cadherin (VE-
cadherin) is the major structural component of endothelial AJ. p120-
catenin protects VE-cadherin from being internalized and is required for
the proper assembly of AJ and the maintenance of barrier function [9].
Endothelial cells (EC) are also engaged in transcellular exchanges by
releasing either soluble mediators, including nitric oxide (NO) and in-
terleukin (IL)-8 that control vascular tone and leukocyte recruitment, or
microvesicles (EMV) that carry a repertoire of proteins, lipids and nu-
cleic acids [10].
Despite its preeminent role in vasoregulation and inflammation, the
vascular endothelium has been insufficiently investigated in CF. CFTR
expression in EC and the involvement of CFTR in endothelial responses
to hypoxia have been reported [11,12]. We and others documented that
CF patients present peripheral biochemical signs of endothelial per-
turbation [13,14]. Moreover, microvascular dysfunction in CF patients
has been recently reported [15]. Together with enhanced oxidant stress,
unresolved inflammation and the extension of life expectancy, en-
dothelial dysfunction could contribute to increase the cardiovascular
risk for CF patients.
In the present report, we investigated the impact of CFTR loss-of-
function on EC activities potentially related to cardiovascular risk and
lung inflammation.
2. Materials and methods
DMEM and 199 media, fetal calf serum (FCS), penicillin and
streptomycin were from Gibco (Waltham, Massachusetts, U.S.A.).
HEPES was from Merk (Darmstadt, Germany). CFTRinh-172, for-
moterol fumarate and anti-p120 catenin antibody were from Santa Cruz
Biotechnology (Dallas, Texas, U.S.A.). IL-1β (human, recombinant) was
from Enzo Life Sciences (NY, USA). Roflumilast N-Oxide (RNO), the
active metabolite of roflumilast was generously provided by Nycomed
(Konstanz, Germany). Rolipram, Formoterol and Cilostamide were from
Calbiochem (Vimodrone, Milano, Italy). Anti-VE-Cadherin antibody
and DRAQ5 were from Abcam (Cambridge, U.K.). Anti-paxillin and
anti-vinculin antibodies were from BD (BD Trasduction Laboratories,
Milano Italy) and Sigma-Aldrich (St Louis, MO, USA), respectively.
Phalloidin-TRITC and fluorescein isothiocyanate (FITC)-conjugated
dextran (FD4; 3-5kDA) were from Sigma (Saint Louis, MO, U.S.A.).
2.1. Cells
Human umbilical vein endothelial cells (HUVEC) were isolated as
previously described [16] and cultured in DMEM/199 medium (50%
volume), endothelial cell growth supplement (100 μg/mL), heparin
(15 U/mL) penicillin-streptomycin (100 μg/mL, each) and FCS (12%) at
37 °C under 5% CO2. Experiments were performed using cells up to the
third passage.
Human pulmonary artery endothelial cells (PAEC) were isolated
from surgical fragments. Segments of human arterial pulmonary en-
dothelial cells (PAEC) were rinsed three times with a solution made of
3.9% saline containing 1% penicillin/streptomycin and fungizone
(0.25 mg/mL) in order to remove blood cells and other contaminants.
Specimens were then washed three times with 3.9% saline containing
250 μg/mL linezolid, 50 U/mL colistin, 25 μg/mL co-trimoxazole and
25 μg/mL amphotericin B and thereafter placed in 50 mL tubes con-
taining DMEM/M199 (50%/50%), 10% FBS, 1% L-Glutamine
(200 mmol/L), 1% Penicillin/Streptomicin (100×), 1% Fungizone
(0.25 mg/mL), 1% ECGF (100×), 1% heparin (100×) plus 250 μg/mL
linezolid, 50 U/mL colistin, 25 μg/mL co-trimoxazole and 25 μg/mL
amphotericin B. Samples were maintained at 4 °C until exposed (usually
within 6–12 h from surgical excision) for 20 min at 37 °C, 5% CO2, 90%
humidity to phosphate-buffered saline (PBS) without calcium and
magnesium containing 2 mg/mL type II collagenase (Worthington
Biochem, Lakewood, NJ). Immediately after the incubation, samples
were moved into a Petri dish (100 mm) containing culture medium
(DMEM-M199, 50% vol/vol), supplemented with 10% FBS, 1% L-
Glutamine, 1% Penicillin/Streptomicin, 1% Fungizone, 1% ECGF, 1%
heparin (EC medium), together with 250 μg/mL linezolid, 50 U/mL
colistin, 25 μg/mL co-trimoxazole and 25 μg/mL amphotericin B, which
were progressively reduced and removed after a week from the explant.
The artery fragments were massaged with a spatula followed by gentle
shacking to detach the endothelial cells, which were collected by cen-
trifugation at 330 x g for 7 min at room temperature. The cell pellet was
suspended with EC medium and seeded on fibronectin (1 mg/cm2)
(Sigma-Aldrich, Saint Louis, MO, USA)-coated cell culture dishes. Cells
were maintained at 37 °C, 5% CO2, 90% until confluent. With this
method, the percentage of cells expressing the endothelial phenotype
was variable from 10 to 50%.
To obtain a virtually pure endothelial population, we enriched EC
using a method developed in our laboratory, based on early adhesion of
EC compared to contaminant cells [17], which gave 95–98% en-
dothelial cells after 3–4 passages. The endothelial phenotype was as-
sessed by immunofluorescence (Suppl. Fig. 1). To this end, 2 × 104
cells were seeded on glass coverslips pre-coated with 1.5% gelatin. The
next day cells were washed with PBS, fixed with 4% paraformaldehyde,
permeabilized with 0.5% saponin and stained overnight at 4 °C with
anti VWF (MA5-14029 Pierce) and CD31 (M0823 Dako) antibodies.
Cells were subsequently exposed to Alexa Fluor® 488-labeled goat anti-
Mouse IgG for 1 h at 4 °C. Draq-5 was used for nuclei staining. High
definition images were acquired using a Zeiss LSM-510 META system




Cells were harvested and scraped into lysis buffer (50 mmol/L Tris,
pH 7.4, 150 mmol/L NaCl, 1% Triton, 1% deoxycholate, 0.1% SDS)
supplemented with protease inhibitors (Roche, Indianapolis, IN, USA).
Lysates were incubated in a rocking platform for 30 min at 4 °C and
then centrifuged at 13,000 rpm for 30 min at 4 °C to remove debris.
Proteins were quantitated with a BCA protein assay kit (Thermo
Scientific, Rockford, IL, USA), separated by SDS-PAGE and transferred
on nitrocellulose membrane. After exposure to 5% nonfat milk in PBS
for 1 h, membranes were probed with a specific primary antibody: anti-
CFTR mAb clones L12B4 and M3A7 (1:100 each; Merck Millipore,
Darmstadt, Germany). Anti-α-tubulin mAb (1:4000; Sigma-Aldrich, St.
Louis, MO, USA) was used as loading control. The binding of primary
antibodies was detected with anti-mouse secondary peroxidase-con-
jugated antibody (1:1000 to detect CFTR, 1:7500 for α-tubulin; Merck
Millipore), and visualized with the clarity western ECL substrate (Bio-
Rad, Hercules, CA, USA). Immunoblot images were acquired with
Alliance 4.7 (UVITEC, Cambridge, UK). The intensity of the relevant
bands was evaluated using the UVI band software package or with the
ImageJ NIH Image Analysis Program.
2.2.2. Flow cytometry
CFTR expression in non-CF and CF-PAEC was also evaluated by flow
cytometry. For surface localization, cells were detached with EDTA and
collected by centrifugation (300 ×g for 10 min). Pellets were sus-
pended with PBS and incubated (1 h at 4 °C) with a mouse monoclonal
anti-human CFTR antibody (CF3) (ThermoFisher) directed against the
amino acid residues 103–107 located within the first extracellular loop.
After removing the excess of primary antibody by centrifugation wash,
cells were incubated with PerCP/Cy5.5-conjugated anti-mouse IgM
(BioLegend, San Diego, CA, USA) for 1 h at 4 °C. For evaluation of
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intracellular CFTR, cells were harvested, fixed with 3% formalin and
permeabilized with FACS lysing and Perm2 solutions (BD) before
staining. Cells were incubated with PBS containing an appropriate
amount of the CFTR antibody MAB25031 (R &D Systems, Minneapolis,
USA), for 1 h at 4 °C. They were then stained with Alex-Fluor 647 anti-
mouse IgG (Invitrogen), as secondary antibody. Secondary antibody-
matched controls were used to assess unspecific fluorescence.
2.3. CFTR activity
2.3.1. Whole-cell patch-clamp recording
Experiments were performed using a Multiclamp 700B amplifier
(Axon Instruments, Molecular Devices, Sunnyvale, CA, USA) and an
upright BX51WI microscope (Olympus, Japan) equipped with Nomarski
optics. Patch electrodes, fabricated from thick borosilicate glasses, were
pulled to a final resistance of 4–6 MΩ. Recordings with leak
current< 100 pA and series resistance> 20 MΩ were discarded. All
recordings were acquired at 50 kHz. Cl− currents were elicited by
stepping from a holding potential of −110 mV to +110 mV with
10 mV increments in voltage clamp configuration. PAEC and CF-PAEC
seeded at 35.000 cells/35 mm petri dishes were bathed in a solution
containing: 140 mmol/L N-methyl D-glucamine; 140 mmol/L HCl;
2 mmol/L CaCl2; 1 mmol/L MgCl2 and 10 mmol/L HEPES (pH 7.4).
Pipettes were filled with a solution containing: 140 mmol/L N-methyl D-
glucamine; 40 mmol/L HCl; 100 mmol/L L-glutamic acid; 0.2 mmol/L
CaCl2; 2 mmol/L MgCl2; 1 mmol/L EGTA; 10 mmol/L HEPES; 2 mmol/
L ATP-Mg (pH 7.2). To activate CFTR conductance, a cAMP-activating
cocktail (400 mmol/L cAMP, 10 mmol/L forskolin, 1 mmol/L IBMX)
was added to the pipette solution. Acquisition and data analyses were
performed using the pCLAMP 10.0 and Clampfit 10.0 software, re-
spectively (Axon Instruments). Statistical analyses were carried out
using Prism 5.0 software (GraphPad Software, San Diego, CA, USA).
2.3.2. Yellow fluorescent protein (YFP)
HUVEC were transfected with the Cl−-sensitive YFP-encoding
vector and plated onto 35 mm fibronectin-coated glass slides. Forty
eight hours post transfection, cells were incubated in a NaCl
(137 mmol/L)-containing buffered solution with Forskolin (20 mmol/
L) plus or minus CFTRinh-172 (10 μmol/L) for 20–30 min. At the in-
dicated time points, NaCl buffer was replaced with a NaI (137 mmol/L)-
containing medium plus or minus CFTRinh-172 (10 μmol/L). The signal
decay caused by YFP quenching as the consequence of the Cl−/I− ex-
change was monitored using an upright fluorescence microscope
(Zeiss), equipped with a Xenon lamp-based Optoscan monochromator
(Cairn), a 20 ×W Plan-Apochromat (N.A.: 1.0; Zeiss) objective and a
16-bit Evolve 512 EMCCD camera (Photometrics). Image acquisition
and storage for offline analysis were performed by using Metamorph
7.7 software (Molecular Devices).
2.4. Endothelial permeability
Permeability to FITC-dextran of EC monolayers was assessed as
previously reported [18]. Briefly, EC were grown to confluency on
gelatin-coated translucent PET membrane porous filters (3 μm pores)
(BD Falcon) and exposed to CFTRinh-172 (10 μmol/L) or DMSO in
medium containing 10% serum for 24 h. Where indicated, IL-1β (5 ng/
mL) was added to cells, 4 h before FITC-dextran (0.5 mg/mL, final
concentration). RNO (100 nmol/L), cilostamide (10 μmol/L) and for-
moterol (100 nmol/L) were added 30 min before CFTRinh-172. FD4
(0,5 mg/mL) was added to the upper compartment of the transwells. At
the indicated times, aliquots of medium (25 μL/well) were collected
from the lower chamber and the amount of FITC-dextran was evaluated
with a fluorimeter plate reader (Pharos, BIO-RAD).
2.5. Transendothelial electric resistance (TEER)
Non-CF-PAEC, exposed or not to 10 μmol/L CFTRinh-172 for 4 h at
37 °C, as well as CF-PAEC were seeded in gelatin-coated 0.4 μm
polyester membrane transwell inserts (Corning, Tewksbury MA, USA)
at 0.4 × 105 cells/well density in complete medium. TEER measure-
ments were carried out when cells reached confluence. In some ex-
periments, cells were treated with CFTRinh-172 (10 μmol/L)
(Calbiochem) for 30 min before addition of IL-1β (10 ng/mL)
(Peprotech, Rocky Hill, NJ, USA) and a mixture of roflumilast N-oxide
(RNO) (100 nmol/L) and formoterol (100 nmol/L). TEER was measured
at the indicated time after treatment by placing the electrodes at the
upper and lower chambers. TEER was recorded at three different points
of the sample cup. Inserts containing medium alone and untreated cells
were used as blank and baseline resistance, respectively. The TEER was
calculated subtracting the blank resistance from the resistance recorded
in the presence of the cells.
2.6. Shear stress
EC were subjected to a shear stress of 5 dyne/cm2 for 30 min as
previously reported [16]. Briefly, EC, grown to confluency on gelatin-
coated glass slides, were placed in a flow chamber under a microscope
within a thermoregulated plexiglass box maintained at 37 °C. En-
dothelial cells were perfused with Hepes-buffered DMEM at a shear
stress of 5 dyne/cm2 for 30 min using a syringe pump (Harvard pump)
and observed by phase contrast microscopy at 20× magnification.
Images were continuously video-recorded (Pro-Series video camera,
High Performance CCD camera, Media Cybernetics, Silver Spring, MD,
USA) and analyzed off-line. The number of cells showing morphological
alterations was evaluated at the end of perfusion. The perfusion
medium was collected to enumerate EMV by flow cytometry. At the end
of perfusion, EC were fixed with 4% paraformaldehyde for confocal
microscopy analysis (see below).
2.7. Adherence junction analysis
The distribution of VE-cadherin, p120-catenin, paxillin and vinculin
in EC was assessed by confocal microscopy. EC were fixed in 4% PFA for
15 min at 37 °C and permeabilized with 0,1% saponin in PBS. The
distribution of VE-cadherin, p120-catenin, paxillin and vinculin was
assessed using rabbit polyclonal or mouse monoclonal antibodies.
Alexa488-conjugated anti-rabbit or anti-mouse Ig antibodies were used
for immunodetection. F-actin was detected by staining with rodhamine-
conjugated phalloidin diluted 1:50 in phosphate buffer. Images were
acquired using an LSM 510 confocal microscopy (Zeiss), equipped with
a ×63 oil immersion objective with appropriate filter sets.
2.8. EMV analysis and enumeration
EMV were identified and numerated by flow cytometry, using a
reported method [19]. EMV scatter properties were confirmed by run-
ning Megamix Plus beads (Biocytex, Marseille, France) at the same
photomultiplier (PMT) voltages used for MV detection. Data were
analyzed using FACSDiva v 6.1.3 (BD), FACSuite v 1.0.5 (BD) and
FlowJo v 8.8.6 (TreeStar, Ashland, OR, USA) software. EMV number
was obtained by volumetric count.
2.9. IL-8 measurements
IL-8 was determined in cell supernatants using a commercially
available ELISA kit (R & D Systems, Minneapolis, MN, USA). HUVEC
were cultured in DMEM and M-199 (50:50) supplemented with fetal
bovine serum (20% vol/vol), bovine brain extract endothelial cell
growth factor (ECGF, 50 μg/mL), and heparin (18 I U/mL) (Eparina
Vister, Marvecs Pharma, Milan, Italy). Cells (1 × 105/well) between
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passage 3 and 5 were seeded in 6-well plates and treated 24 h after
reaching 90% confluence. Confluent cell monolayers were washed
twice with DPBS, fresh medium consisting of DMEM:M-199 (50:50)
plus 0.5% endotoxin free bovine serum albumin (BSA) was added, and
cells recovered at 37 °C for 30 min. HUVEC were treated with CFTR-172
(10 μmol/L) (10 min) followed by TNF-α (0.5 μg/mL, Peprotech,
London, UK). After 4 h, the supernatants were collected, centrifuged ad
used for ELISA measurements.
2.10. Nitric oxide determination
Nitric oxide (NO) production by HUVEC was determined as pre-
viously reported [20]. Briefly, HUVEC, between the third and fifth
passage, were grown to confluence at 1.5 × 104 in 6 multi-well plates
using a medium enriched with 20% FCS, 10 μg/mL heparin and 50 μg/
mL ECGF. Cells were made quiescent with 0.5% FBS for 2 h and then
stimulated with 100 nmol/L insulin or 2 μmol/L ionomycin for 15 min
at 37 °C. When present L-Name was added 40 min before the stimulus,
whereas CFTRinh-172 (10 μmol/L) was added to cells 10 min before the
stimulus. At the end of the incubation, HUVEC were collected with a
Hepes-Na + buffer containing CaCl2. NO production was evaluated by
conversion of L-(3H)-arginine into L(3H)-citrulline.
2.11. eNOS and AKT phosphorylation
eNOS phosphorylation was evaluated by flow cytometry. To this
end, 1 × 106 cells/sample were washed and fixed with 1 mL FACS
Lysing solution (BD Biosciences). Cells were permeabilized and in-
cubated for 30 min at 4 °C in the dark with the primary antibody mix
containing PBS 1X + total eNOS (1:500) and phospho eNOS (Ser1177,
1:500). After incubation with the secondary antibody mix (PBS 1X
+ Alexa 488 anti-mouse 1:1500, Alexa 488 anti-rabbit 1:1500) for
30 min at 4 °C in the dark, cells were washed and suspended with
500 μL PBS 1X. Cells were analyzed with a FACSCanto II flow cytometer
(three lasers, eight-color configuration), equipped with the FACSDiva
software v.6.1.3 (BD Biosciences).
Fig. 1. CFTR expression and activity in endothelial cells.
(A) Western blotting. Thirty micrograms of total protein lysate from PAEC and 16HBE were blotted on nitrocellulose membrane. Immunodetection was performed with anti-human CFTR
C-terminus antibody clone 24-1 (MAB25031, R & D systems) and anti-CFTR clone M3A7 (05-583, Upstate/Millipore). Each primary antibody was diluted at 1:500. Secondary Anti-Mouse
Peroxidase conjugate antibody was used at 1:3000 dilution. (B) Flow cytometry. Membrane CFTR was determined in cells, stained with anti-CFTR Ab that recognizes amino acid residues
103-117 in the first extracellular loop of human and rabbit CFTR (MA1-935 IgM, Pierce, 1:100). Histograms depict isotype and anti-CFTR staining of PAEC and CF2-PAEC. (C) CFTR
activity in HUVEC. HUVEC (0.5 × 106 cells) were transfected with the Cl− sensitive YFP-encoding vector (1 μg) using the Amaxa Nucleofector kit (program U001). Forty eight hours post
transfection, cells were incubated in a NaCl (137 mmol/L) buffered solution containing Forskolin (20 μmol/L) plus or minus CFTRinh-172 (10 μmol/L) for 20–30 min at 37 °C and YFP
fluorescence intensity was measured for 1 min before replacement of NaCl with a NaI (137 mmol/L) buffer plus or minus CFTRinh-172 (10 μmol/L). The signal decay caused by YFP
quenching due to the Cl−/I− exchange was monitored for 1 min.
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For AKT phosphorylation, cell lysates (30 μg) were immunoblotted
with anti-AKT (Cell Signaling Technology Inc.), anti-Ser473-Akt (Cell
Signaling Technology, Inc.) and β-actin (Sigma-Aldrich) primary anti-
bodies, followed by peroxidase-conjugated secondary antibodies.
Proteins were detected using enhanced chemiluminescence and quan-
tified with a computerized densitometric system. Data of AKT phos-
phorylation were normalized against total AKT content.
Autoradiographs were quantified using the Molecular Analyst software
(Bio-Rad Laboratories).
2.12. Statistical analysis
Only 2-tailed probabilities were used for testing statistical sig-
nificance, and p < 0.05 was considered statistically significant.
3. Results
3.1. CFTR expression and activity in EC
CFTR expression was evaluated by western blotting and flow cyto-
metry. Both HUVEC and PAEC express the mature form of CFTR (band
C), which was more evident in PAEC (Fig. 1A). Membrane CFTR was
assessed by flow cytometry (Fig. 1B). CFTR activity was evaluated by
YFP fluorescence quenching in HUVEC (Fig. 1C) and patch clamping in
PAEC (Fig. 1D). Electrophysiological recordings in whole cell config-
uration showed the induction of chloride currents by a cAMP-increasing
cocktail (cAMP). This effect was blocked by CFTRinh-172, a selective
CFTR inhibitor [21] (Fig. 1D). CFTR expression and activity was also
determined in PAEC isolated from the explanted lungs of two CF pa-
tients with the following genotypes: G542X/1717-1G->A (CF1) and
F508del/F508del (CF2) (Suppl. Fig. 1). As expected, these cells had
reduced membrane CFTR (Fig. 1B). Consistent with this, CF2-PAEC did
not respond to cAMP (Fig. 1E), which instead enhanced PAEC current
density (pA/pF) (Fig. 1F).
(D-F) Whole-cell patch clamping. Representative chloride currents
in PAEC (D), either left untreated (Basal), or exposed to cAMP-in-
creasing agents (cAMP) alone or in combination with CFTRinh-172
(10 μmol/L) or in CF-PAEC (E) exposed or not to cAMP. Currents were
recorded in 200 ms voltage steps from−110 to +110 mV with 10 mV
increments from a holding potential of −40 mV. Averaged current/
voltage relationship in PAEC (n = 16); PAEC + cAMP (n = 15);
PAEC + cAMP/CFTRinh-172 (n = 14); CF-PAEC (n = 10); CF-
PAEC + cAMP (n = 10) are shown in the lower panels of (D) and (E),
respectively. (F) Bars show chloride current density (pA/pF) recorded
at +110 mV in the same samples of panel (D) and (E). Data are
mean ± SEM. *p < 0.05; **p < 0.01, One Way Anova (Kruskal-
Wallis test).
3.2. CFTR regulates endothelial barrier function
Since CFTR controls epithelial monolayer integrity [22], we in-
vestigated CFTR impact on EC permeability to macromolecules and
transendothelial electrical resistance (TEER). CFTRinh-172 significantly
increased cell permeability to dextran and reduced TEER (Fig. 2A and
B). Remarkably, CF2-PAEC displayed lower basal TEER compared to
normal PAEC, in a similar range as PAEC exposed to CFTRinh-172
(Fig. 2B).
Changes in endothelial permeability mainly result from alterations
of intercellular junctions. Using confocal microscopy, we analyzed the
impact of CFTR blockade on expression and distribution of VE-cadherin
and p120 catenin, main components of AJ in HUVEC. As expected, in
untreated HUVEC, VE-cadherin formed a continuous ribbon at the cell
periphery and wide reticular structures, likely corresponding to regions
of intercellular membrane overlaps (Fig. 2C). We observed a similar
pattern for p120 catenin (Fig. 2C). CFTR blockade altered the junctional
structures, determining the appearance of numerous gaps between
adjacent cells, in which VE-cadherin and p120 catenin disappeared
from the membrane. Consistent with this, areas of intercellular contact
exhibited reduced VE-cadherin and p120 catenin accumulation as well
as reduced extension of reticular structures, being these effects more
pronounced in IL-1β-treated HUVEC (Fig. 2C).
3.3. CFTR blockade alters endothelial stability under shear stress
To assess the impact of CFTR dysfunction in a more physiological
setting, we subjected HUVEC and PAEC to shear forces (5 dyne/cm2,
30 min). Untreated HUVEC retained their cobblestone-like appearance
and tight intercellular membrane apposition (Video 1).
In contrast, CFTRinh-172-treated cells showed significant altera-
tions of cell morphology and intercellular junctions. A significant
number of EC displayed membrane blebs at the apical surface and
cellular edges. Blebbing evolved into shrinking of the cell body, dis-
ruption of cell-cell contacts and opening of intercellular gaps (Video 2).
These events were more pronounced in IL-1β-treated HUVEC
(Videos 3 and 4).
PAEC subjected to shear showed a similar behavior (Videos 5 and
6).
CFTRinh-172 increased the number of EC undergoing morpholo-
gical alterations after 30 min perfusion in unstimulated (3.6 ± 0.8 vs
17.3 ± 2.0/cells per field; p < 0.05) and IL-1β-treated EC
(7.2 ± 0.8 vs 35.4 ± 1.9/cells per field; p < 0.05) (Fig. 3A). Such
changes were not appreciated in the absence of shear (results not
shown).
We also analyzed the organization of the endothelial junctions
under shear. HUVEC subjected to shear exhibited VE-cadherin dis-
tribution at the cell periphery, organized in reticular structures at in-
tercellular membrane overlaps (Fig. 3B). CFTRinh-172 induced the
formation of gaps between adjacent cells, in which the accumulation of
VE-cadherin was reduced (Fig. 3B). These effects were more pro-
nounced in the presence of IL-1β (Fig. 3B). Notably, paxillin and vin-
culin, two focal adhesion (FA)-associated proteins, accumulated inside
the blebs (Fig. 3C). This is consistent with the hypothesis that CFTR
dysfunction can affect the functional integrity of FA in EC.
3.4. CFTR loss-of-function alters EMV release and activity
Membrane blebs are usually associated with the formation of MV.
EMV are released during inflammation or apoptosis and regarded as
biological indices of endothelial dysfunction [23]. We, therefore, col-
lected and enumerated EMV in media from HUVEC or PAEC exposed or
not to CFTRinh-172. CFTR blockade clearly stimulated EMV generation
both by resting and IL-1β-treated cells (Fig. 4A). Consistent with this,
CF2-PAEC released a higher number of EMV (CF-EMV), compared to
non-CF PAEC (Fig. 4B). In contrast to EMV from non-CF PAEC, CF-EMV
were unable to stimulate proliferation of recipient PAEC or CF2-PAEC
(Fig. 4C). This effect was not related to differences in EMV uptake by
recipient cells (results not shown).
3.5. cAMP-increasing agents correct the loss of EC barrier function triggered
by CFTR blockade
The cAMP/PKA signaling is key for the maintenance of the en-
dothelial barrier function [24]. The cAMP pool is physiologically con-
trolled by the combined action of type 3 and 4 phosphodiesterases
(PDE) and adenylyl cyclase. Also, the activation of β-adrenergic re-
ceptors stimulates adenylyl cyclase and improves endothelial barrier
function in vitro and in vivo [25]. On the other hand, PDE inhibitors
and β-adrenergic agonists have been reported to improve CFTR activity
in epithelial cells as well as in murine hematopoietic stem/progenitor
cells [26,27]. Based on this evidence, we evaluated the efficacy of se-
lective PDE3 and PDE4 inhibitors in combination with a β2-adrenergic
agonist to counteract CFTR blockade-induced endothelial dysfunction.
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Treatment with a combination of cilostamide (PDE3 inhibitor), ro-
flumilast N-oxide (RNO) (PDE4 inhibitor) and formoterol, a long acting
β2-adrenergic agonist, corrected permeability and TEER, both in PAEC
exposed to CFTRinh-172 and CF1-PAEC (Fig. 5A–C), and reduced VE-
cadherin and p120 catenin alterations at the intercellular junctions in
CFTRinh-172-treated EC, both, under basal or inflammatory conditions
(Fig. 5D). Remarkably, under shear these agents abrogated alterations
in cell morphology and monolayer integrity, triggered by CFTR
blockade in HUVEC (Fig. 5D,E and Videos 7,8) as well as in PAEC
(Videos 9,10).
3.6. CFTR controls key endothelial-dependent regulatory mechanisms of
vascular tone and leukocyte recruitment
To obtain further evidence of CFTR signaling in endothelial cells, we
evaluated the impact of CFTR blockade on two main endothelial-de-
rived modulators of the vascular tone and inflammation, namely NO
and IL-8. CFTR blockade suppressed insulin-induced NO generation by
HUVEC (Fig. 6A). This was related to the inhibition of eNOS and AKT
phosphorylation (Fig. 6B and C). On the other hand, CFTR blockade
significantly enhanced IL-8 release by EC (Fig. 6D). These results in-
dicate that endothelial cells expressing a dysfunctional CFTR, acquire a
phenotype compatible with increased vascular tone and excessive PMN
recruitment, thus contributing to sustain inflammation.
4. Discussion
The concept of CF as a systemic disorder affecting different cells,
tissues and functions has been recently reinforced by the evidence of
CFTR expression and activity in a variety of cells. We uncovered CFTR
in platelets [5], whereas CFTR expression and activity has been ob-
served in leukocytes [6,7], smooth muscle cells [28] and stem cells
[29]. Moreover, conditional knockouts have provided valuable in-
formation on CFTR bioactions and signaling in non-respiratory cells
[30,31].
Here, we examined CFTR expression and function in EC. Since little
was known regarding endothelial functions controlled by CFTR in EC,
we undertook a horizontal approach by exploring the consequences of
CFTR loss-of-function on a variety of EC key regulatory activities of
vascular homeostasis and inflammation. For this scope, we employed
EC isolated for the first time from fragments of the pulmonary artery
from explanted CF lungs [17] and compared data with normal EC cells
exposed to CFTRinh-172 as an in vitro pharmacological model of CF.
CFTR activity in these cells was carefully evaluated (Fig. 1D–F) and the
two models were always consistent.
Based on CFTR signaling in epithelial cells and histological analyses
of CFTR lungs [22,32], we initially evaluated CFTR involvement in the
regulation of endothelial barrier function. Data with HUVEC, PAEC and
CF-PAEC were consistent to show that CFTR loss-of-function impaired
the EC barrier function (Fig. 2A and B). This observation is in line with
Fig. 2. CFTR loss-of-function increases EC permeability, while reducing TEER and VE-cadherin and p120-catenin membrane expression.
(A) Confluent HUVEC, grown on culture inserts (3 μm pore size) set into 12 well plates, were incubated in the presence of CFTRinh-172 (10 μmol/L) or DMSO vehicle. After 24 h, FITC-
dextran (0.5 mol/L) was added to the upper compartment. At the indicated times, aliquots (25 μL) of medium were collected from the lower compartment and their fluorescence
monitored with the Pharos Fx, Molecular Imager. Results are expressed as Arbitrary Fluorescence Units (counts × 103/mm2). The graph shows mean ± SEM; n = 5; *p < 0.05 (Student
t-test vs DMSO). (B) Confluent PAEC were exposed to DMSO or CFTRinh-172 (10 μmol/L) for 4 h. CF1-PAEC (G542X/1717-1G->A) and CF2-PAEC (F508del/F508del) were examined in
parallel. TEER was measured using an EVOM analyzer as reported in methods. Resistance was expressed in Ohm (Ω) subtracting blank values. Results are mean ± SEM from 3
measurements at different passage with duplicates; *p = 0.0088; **p = 0.0063; ***p = 0.0028. (C) Confluent HUVEC, grown on culture slides, were exposed to CFTRinh-172 (10 μmol/
L) or DMSO for 24 h. IL-1β (5 ng/mL) was added to cells 4 h before fixation with 4% paraformaldheyde. HUVEC were permeabilized and stained for VE-cadherin or p120-catenin, using
specific polyclonal antibodies. Confocal microscopy images were acquired at ×630 magnification. Images are representative of n = 3 experiments.
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Fig. 3. Impact of CFTR blockade on EC under shear stress.
(A) Confluent, resting or IL-1β-treated (5 ng/mL, 4 h) HUVEC perfused (30 min) with DMEM containing CFTRinh-172 (10 μmol/L) or DMSO, at 5 dynes/cm2 (upper panel). EC mor-
phology was monitored during perfusion and video recorded. Cells that underwent morphologic alterations under shear were enumerated at the end of perfusion. Bars (lower panel)
report the number of cells showing blebs, shrinking and retraction per optical field (0.7 mm2). Values are mean ± SEM; (n = 11 for resting and n = 53 for IL-1β-treated HUVEC);
*p < 0.05 vs vehicle (ANOVA for repeated measurements, Tukey test). (B) VE-cadherin membrane expression. HUVEC were treated as in A, fixed with 4% paraformaldheyde and
permeabilized. VE-cadherin was visualized using a specific polyclonal antibody. Confocal microscopy images were acquired at ×630 magnification. The image is representative of n = 3.
(C) Accumulation of paxillin (left) and vinculin (right) in CFTRinh-172-induced blebs. HUVEC were subjected to shear forces ad fixed as above. Paxillin and vinculin (green) were
visualized using specific polyclonal antibodies and F-actin (red), by rhodamine-conjugated phalloidin. Images were acquired at ×630 magnification (CROP × 3). The image is re-
presentative of n = 3, with cells from umbilical cords from different donors.
Fig. 4. EMV in CF. (A) HUVEC were exposed or not to IL-1β (5 ng/mL, 4 h), CFTRinh-172 (10 μmol/L) or the combination of the two. Cells were subjected to 20 dynes/cm2 shear for
40 min. Flow fluid (~50 mL) was collected and EMV were enumerated by flow-cytometry. Bars represent mean ± SD from n = 3. *p < 0.01. (B) Cells were grown for 48 h in 100 mm
Petri dishes. The supernatant (~10 mL) was collected and EMV were counted by flow cytometry. Counts normalized for cell number. Bars represent mean ± SEM of 3 enumerations.
*p = 0.004. (C) PAEC or CF-PAEC (2.4 × 104) were incubated with EMV or CF-EMV (1:10) for 24 h in the presence of 2% FBS. Cells were counted and their viability was assessed by
trypan blue staining. Results are mean ± SEM from n = 2 with duplicates. *p = 0.005 vs PAEC incubated with EMV; **p = 0.002 vs CF-PAEC incubated with EMV.
L. Totani et al. BBA - Molecular Basis of Disease 1863 (2017) 3243–3253
3249
recent findings [33] and brings up the question of whether and to what
extent such impairment can contribute to sustain leukocyte infiltration
and organ inflammation in CF [34].
The molecular events underlying the loss of EC barrier function
upon CFTR blockade include the perturbation of the membrane dis-
tribution of VE-cadherin and p120-catenin, main AJ components
(Fig. 2C). VE-cadherin mediates homotypic EC interactions [35] and
anchors AJ to the cortical actin network [36], whereas p120 catenin
inhibits VE-cadherin internalization [8]. VE-cadherin and p120 catenin
localization at the cell membrane is required for proper AJ assembly
and efficient barrier function [35]. Agents, like IL-1β that promote VE-
cadherin endocytic internalization, also disrupt endothelial barrier
function [36]. Although we did not examine VE-cadherin and p120
internalization, we clearly observed a great exacerbation of this phe-
nomenon when IL-1β was present (Fig. 2C). Thus, CFTR activity con-
tributes to maintain vascular homeostasis, particularly during an in-
flammatory response.
The impact of CFTR dysfunction on EC morphology and stability
was dramatically evident under physiological shear. This setting
allowed us to unravel events barely visible under static conditions, such
as retraction, cell shrinking, membrane blebs formation and release of
cellular vesicles. These events were exacerbated by IL-1β (Videos 3 and
5) and were visible only in cells exposed to CFTRinh-172 (Fig. 3 and
Videos 2, 4 and 6). In addition to changes in VE-cadherin and p120
catenin, the shear stress experiments revealed the accumulation in the
membrane blebs of paxillin and vinculin (Fig. 3), main components of
the FA complexes [37], suggesting that CFTR also controls adhesive
interaction between endothelial cells and the extracellular matrix. This
can also influence barrier function [38].
Consistent with morphology changes under flow, CFTR loss-of-
function was associated with enhanced release of EMV (Fig. 4). Al-
though an increased number of leukocyte-derived MV was found in
sputum from CF patients [39], our results indicate that CFTR can di-
rectly control MV biogenesis. This implies that CFTR dysfunction not
only affects the functions of singular cells, but also MV-mediated in-
tercellular communications. Data reported in Fig. 4C are consistent
with this hypothesis. It is, in fact, clear that regardless of the recipient
cells (non-CF or CF), EMV released by CF cells were unable to stimulate
Fig. 5. cAMP increasing agents protect EC from CFTR loss-of-function.
(A) Cell permeability. Confluent HUVEC were incubated with CFTRinh-172 (10 μmol/L), in the presence or not of a combination of 100 nmol/L roflumilast n-oxide, 10 μmol/L cilos-
tamide and 100 nmol/L formoterol (R.C.F.). After 24 h, FITC-dextran was added to the upper compartment. IL-1β (5 ng/mL) was added 4 h before FITC-dextran. At the indicated time,
25 μL aliquots of medium were collected from the lower compartment and fluorescence quantitated with a Pharos Fx, Molecular Imager. Results are expressed as Arbitrary Units of
Fluorescence (counts × 103/mm2). Graph shows mean ± SEM; n = 3; *p < 0.05 vs DMSO (Student t-test). B and C PAEC (B) were treated with CFTRinh-172 (10 μmol/L) for 30 min
before stimulation with IL-1β (10 ng/mL) alone or in combination with R.C.F. TEER was recorded after 4 h. Bars depict mean ± SEM from n = 4 (*p = 0.0088; **p = 0.016;
***p = 0.0044). (C) CF1-PAEC were treated and processed as above. Bars are mean ± SEM from 5 separate measurements with cells at different passages (*p = 0.025; **p = 0.0001).
(D) Confluent HUVEC were exposed to CFTRinh-172 (10 μmol/L) alone or in combination with IL-1β (5 ng/mL), in the presence or not of R.C.F. for 24 h. Cells were permeabilized and
stained for VE-cadherin and p120 catenin using specific polyclonal antibodies. Confocal microscopy images were acquired at ×630 magnification. The image is representative from
n = 3, with cells from umbilical cords from different donors. (E) IL1-β-treated HUVEC were perfused with medium containing CFTRinh-172 (10 μmol/L), alone or in combination with
R.C.F. for 30 min, at 5 dyne/cm2. Endothelial cells showing blebbing, shrinking and retraction were enumerated by off-line analysis of video recordings. Values are the mean ± SEM of
n = 14 (*p < 0.05, ANOVA for repeated measurements).
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cell proliferation as efficiently as EMV from non-CF cells. This is likely
due to changes in content, since no changes in EMV uptake was de-
tected (results not shown).
Altogether, our shear stress data support the view of CFTR being a
sensor of cyclic strain that triggers integrated biochemical signaling
aimed at coordinating physical cell adaptation and responses to me-
chanical stimuli, such as blood flow in the case of EC and respiratory
cycles for epithelial cells. Indeed, airway epithelial cells respond to
mechanical stress with the release of inflammatory mediators, such as
oxygen radicals and cytokines, including IL-8, as well as with cytos-
keleton re-organization [40].
Results from experiments with agents that increase cAMP may be
helpful to define the signaling pathways underlying the CFTR-depen-
dent control of EC barrier function. We consistently observed that the
combination of PDE inhibitors and β-adrenergic agonists normalized EC
integrity as well as VE-cadherin and p120 catenin distribution (Fig. 5
and Videos 8 and 10). These results may further support the use of these
agents that can also directly stimulate CFTR activity [26,27], as a
therapeutic option to normalize both epithelial and endothelial func-
tions in CF patients. On the other hand, the present data suggest that at
least some of the endothelial alterations consequent to CFTR-loss-of-
function may be related to cAMP signaling. Indeed, that CFTR may act
as a multidirectional signal generator to many cellular pathways that
involve cAMP is an emerging concept (reviewed by Kunzelmann &
Mehta) [41]. Along these lines, CFTR regulation of PKA activation
during sperm capacitation has been reported [42].
Having established that CFTR dysfunction profoundly affected EC
dynamics, we next asked whether it could also modify functional in-
dices, related to inflammation and vascular biology. We focused on NO,
a main regulator of the vascular tone and inflammatory responses [43]
observing that CFTR blockade suppressed insulin-induced NO genera-
tion by EC (Fig. 6). This is consistent with our early data with platelets
[5] and with the observation of reduced nasal NO in CF patients [44].
Here, however, we provide a mechanistic background for the reduced
NO production by CF patients, as we show that CFTR controls the
phosphorylation and the activity of eNOS (Fig. 5), likely by acting on
AKT phosphorylation (Fig. 5C). It has to be denoted that CFTRinh-172
did not alter calcium ionophore-induced NO release, suggesting that
CFTR blockade may interfere with insulin signaling. This is consistent
with recent data in CF airways [45]. Moreover, since CF patients often
suffer from diabetes mellitus, mainly due to reduced CFTR-regulated
insulin secretion [46], it is likely that CFTR-dependent changes in in-
sulin sensitivity may play a role in this setting.
Together with data showing that CFTR expressed by vascular
Fig. 6. CFTR inhibition blocks NO generation, eNOS and AKT phosphorylation, and stimulates IL-8 release.
(A) HUVEC (1.5 × 104) between the third and fifth passage, were grown in a medium containing 20% FCS, 10 μg/mL heparin and 50 μg/mL ECGF. Cells were made quiescent with 0.5%
FBS for 2 h and then stimulated with 100 nmol/L insulin for 15 min at 37 °C. When present L-NAME was added 40 min before the stimulus, whereas CFTRinh-172 (10 μmol/L) was added
to cells 10 min before the stimulus. At the end of the incubation, HUVEC were collected with a Hepes-Na+ buffer containing CaCl2. NO production was evaluated by conversion of L-(3H)-
arginine into L(3H)-citrulline. Bars represent mean ± SD from n = 3 (*p = 0.017; **p = 0.0027). (B) HUVEC were exposed to insulin (100 nmol/L), in the presence or not of CFTRinh-
172 (10 μmol/L) for the indicated time, and eNOS phosphorylation was evaluated by flow cytometry. To this end, 1 × 106 cells/sample was fixed with 1 mL FACS Lysing solution (BD
Biosciences). Cells were permeabilized and incubated for 30 min at 4 °C in the dark with the primary antibody mix containing PBS 1X + total eNOS (1:500) and phospho eNOS (Ser1177,
1:500), followed by the secondary antibody mix (PBS 1X + Alexa 488 anti-mouse 1:1500, Alexa 488 anti-rabbit 1:1500). Cells were washed and analyzed with a FACSCanto II flow
cytometer. Results are mean ± SD from n = 3 (*p = 0.048 vs Insulin 15′; **p = 0.046 vs Insulin 5′). (C) Cell lysates (30 μg) were immunoblotted with anti-Akt, anti-Ser473-Akt and β-
actin primary antibodies, followed by peroxidase-conjugated secondary antibodies. Data of Akt phosphorylation were normalized for total Akt. Autoradiographs were quantitated using
the Molecular Analyst software. Images from a representative experiment are reported in the upper panel. Bars represent mean ± SD from n = 3. ***p = 0.002 vs Insulin 2′; **p = 0.01
vs Insulin 5′; *p = 0.04 vs Insulin 10′; *p = 0.04 vs Insulin 15′. (D) HUVEC monolayers were exposed to CFTRinh-172 for 4 h. Medium was collected as assayed for IL-8 by ELISA. Bars
represent mean ± SD of n = 4 (*p = 0.002).
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smooth muscle cells is involved in the regulation of hypoxic pulmonary
vasoconstriction [12], these results suggest that CFTR dysfunction is
associated with the impairment of key vasoregulatory mechanisms,
which may have pathogenetic consequences. Indeed, recent studies
have pointed out the risk of cardiovascular events in CF patients [47].
These risks may be now more appreciable, due to the extension of the
lifespan of these patients.
Interestingly, CFTR blockade upregulated IL-8 generation by EC
(Fig. 5D). This confirms the acquisition of an inflammatory-prone
phenotype by EC with dysfunctional CFTR, since IL-8 is a main che-
motactic agent for PMN. It also supports the similarity in responses
between epithelial and endothelial cells [48] and suggests that EC can
significantly contribute to the increase in circulating IL-8 in CF patients
[49].
In conclusion, we report that CFTR controls homeostatic functions
of EC, providing insights into CFTR pathophysiology in the vascular
endothelium. Although, we did not explore in detail the mechanisms
involved in these, previously unappreciated, CFTR functions, the evi-
dence that drugs that modulate cAMP signaling can protect EC from
alterations triggered by CFTR dysfunction, while opening avenues for
innovative pharmacological approaches to CF, suggests that at least
some of the endothelial alterations triggered by CFTR-loss-of-function
may be related to cAMP signaling.
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